BGCS 2019 - Annual Scientific Meeting of the British Gynaecological Cancer Society
Jul 11 - Jul 12, 2019 | CambridgeUK
LARVOL is not affiliated with Annual Scientific Meeting of the British Gynaecological Cancer Society and all trademarks, logos, and brand names are property of their respective owners
Showing 5 abstracts linked to Trials
Effect of Maintenance Rucaparib on Post-progression Outcomes in Patients with Platinum-Sensitive, Recurrent Ovarian Carcinoma (OC) and Updated Safety Data from the Phase 3 Study ARIEL3
Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization From GARNET, a Phase 1/2 Clinical Trial of the Anti–PD-1 Monoclonal Antibody Dostarlimab (TSR-042) in Patients With Recurrent or Advanced MSI-H and MSS Endometrial Cancer (EC)
ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017-004557-17; NCT03522246): A Randomised, DoubleBlind, Placebo-Controlled, Phase 3 Study of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitor Rucaparib + the PD-1 Inhibitor Nivolumab Following Frontline Platinum-Based Chemotherapy in Ovarian Cancer
Anti-tumour Activity and Updated Safety of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitor Rucaparib as Monotherapy in Patients with Platinum-Sensitive, Relapsed, BRCA-Mutated, High-Grade Ovarian Cancer
Real-world data from Single Cancer Centre Institution Experience of Niraparib maintenance in patients with platinum-sensitive, second remission onwards, Ovarian Cancer patients – 2 year follow up.